Chimerix Initiates A Multi Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced that the Company has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for smallpox infection. This trial will study the pharmacokinetics and safety of three doses of the drug given to healthy volunteers. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 15th, 2007